Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland.
Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland.
复制标题
DOI：
10.1007/s00038-020-01494-0
复制
发表时间：
2020-12
影响因子：
4.6
通讯作者：
Corona Immunitas Research Group
中科院分区：
文献类型：
--
作者：
West EA;Anker D;Amati R;Richard A;Wisniak A;Butty A;Albanese E;Bochud M;Chiolero A;Crivelli L;Cullati S;d'Acremont V;Epure AM;Fehr J;Flahault A;Fornerod L;Frank I;Frei A;Michel G;Gonseth S;Guessous I;Imboden M;Kahlert CR;Kaufmann L;Kohler P;Mösli N;Paris D;Probst-Hensch N;Rodondi N;Stringhini S;Vermes T;Vollrath F;Puhan MA;Corona Immunitas Research Group
评估SARS-CoV-2感染在一般人群和亚群中传播的血清阳性率研究是评估缓解和疫苗接种政策以及了解国家一级疾病传播情况和与国际社会进行比较的关键。Corona Immunitas是瑞士公共卫生学院（SSPH+）实施的一项协调的、基于人群的血清阳性率研究计划。将包括28 340多名随机挑选和按年龄分层的参与者，其中有一些区域的特殊性。还计划在易受影响和高度受影响的亚群中开展更多研究。这些研究将评估大流行期间的人群免疫状况。来自日内瓦的第一阶段（大流行的第一波）估计显示，到2020年5月9日，血清阳性率稳步上升至10.8%（95% CI 8.2-13.9，n = 775）。自6月以来，苏黎世、洛桑、巴塞尔城市/州、蒂奇诺和弗里堡共招募了5973名参与者。Corona Immunitas将产生可靠、可比和高质量的血清学和流行病学数据，广泛覆盖瑞士和几个亚群，为经济和社会部门的卫生政策和决策提供信息。ISRCTN Registry：https://www.isrctn.com/ISRCTN18181860.本文的在线版本（10.1007/s 00038 -020-01494-0）包含补充材料，可供授权用户使用。
Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and subgroups are key for evaluating mitigation and vaccination policies and for understanding the spread of the disease both on the national level and for comparison with the international community. Corona Immunitas is a research program of coordinated, population-based, seroprevalence studies implemented by Swiss School of Public Health (SSPH+). Over 28,340 participants, randomly selected and age-stratified, with some regional specificities will be included. Additional studies in vulnerable and highly exposed subpopulations are also planned. The studies will assess population immunological status during the pandemic. Phase one (first wave of pandemic) estimates from Geneva showed a steady increase in seroprevalence up to 10.8% (95% CI 8.2–13.9, n = 775) by May 9, 2020. Since June, Zurich, Lausanne, Basel City/Land, Ticino, and Fribourg recruited a total of 5973 participants for phase two thus far. Corona Immunitas will generate reliable, comparable, and high-quality serological and epidemiological data with extensive coverage of Switzerland and of several subpopulations, informing health policies and decision making in both economic and societal sectors. ISRCTN Registry: https://www.isrctn.com/ISRCTN18181860. The online version of this article (10.1007/s00038-020-01494-0) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
28.3
作者：
Gorbalenya, Alexander E.;Baker, Susan C.;Ziebuhr, John
通讯作者：
Ziebuhr, John
影响因子：
6.3
作者：
Khalatbari-Soltani, Saman;Cumming, Robert G.;Kelly-Irving, Michelle
通讯作者：
Kelly-Irving, Michelle
影响因子：
158.5
作者：
McMichael, Temet M.;Currie, Dustin W.;Duchin, Jeffrey S.
通讯作者：
Duchin, Jeffrey S.
影响因子：
168.9
作者：
Pollan, Marina;Perez-Gomez, Beatriz;Yotti, Raquel
通讯作者：
Yotti, Raquel
关于流感的血清ePIDEMIologic研究报告的共识陈述（Roses-I陈述）：频闪陈述的扩展。
影响因子：
4.4
作者：
Horby PW;Laurie KL;Cowling BJ;Engelhardt OG;Sturm-Ramirez K;Sanchez JL;Katz JM;Uyeki TM;Wood J;Van Kerkhove MD;CONSISE Steering Committee
通讯作者：
CONSISE Steering Committee